MaaT Pharma (MAAT) AI Stock Analysis

• Market Cap: €75.39M
• Dividend Yield: N/A
• Average Volume (3M): 18.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: 44.34%
• EPS Growth: -27.37%
• Country: FR
• Employees: 59
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -1.02
• Shares Outstanding: 16,135,971
• 10 Day Avg. Volume: 27,047
• 30 Day Avg. Volume: 18,806
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €18.00
• Price Target Upside: 284.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 39 Underperform
• Price Target: €4.00 ▼(-14.53%Downside)

MaaT Pharma's overall stock score is primarily impacted by its challenging financial performance with ongoing losses and high leverage. The technical analysis further indicates bearish momentum, and the negative valuation metrics provide little support for an investment case. Addressing these financial and technical challenges is crucial for improving future prospects.

Positive Factors

Clinical Trials

The ALS data present a compelling case for further exploration in a P2 trial and external collaboration.

Regulatory Approvals

MaaT013 is about to secure its first regulatory approval, and MaaT033 has demonstrated its excellent safety in both post allo-HSCT and ALS.

Negative Factors

Financial Position

The pressing issue is to secure additional funding, as the company's cash position only extends to the second quarter of 2025.

Investment Risks

Risks to the investment thesis include failure of clinical trials, regulatory requirements for additional studies, and the potential need to raise additional funds under poor market conditions.

MaaT Pharma Business Overview & Revenue Model

Company Description

MaaT Pharma (MAAT) is a biopharmaceutical company specializing in the development of microbiome-based therapies. The company operates in the healthcare sector, focusing on restoring the balance of gut microbiota to treat various diseases, particularly in the fields of oncology and hematology. MaaT Pharma's core products include a pipeline of proprietary biotherapeutics designed to improve patient outcomes through microbiota restoration.

How the Company Makes Money

MaaT Pharma makes money primarily through the development and commercialization of its microbiome-based therapeutics. The company generates revenue from licensing agreements, research collaborations, and milestone payments with pharmaceutical companies and research institutions. Additionally, MaaT Pharma may earn income from grants and funding related to its research and development activities. Key partnerships with academic and commercial entities contribute to its earnings by facilitating the advancement and potential market introduction of its therapeutic products.

MaaT Pharma Financial Statement Overview

Summary

MaaT Pharma is experiencing financial difficulties typical of biotech firms, with ongoing losses and high leverage. Despite revenue growth, significant operating losses and negative cash flows are concerning. The high debt levels on the balance sheet and negative cash flow suggest challenges in achieving financial stability.

Income Statement

MaaT Pharma has shown revenue growth over the years, with a 44.36% increase from 2023 to 2024. However, the company is still operating at a loss, with a negative net profit margin of -898.45% in 2024. The gross profit margin in 2024 was 61.13%, indicating some efficiency in covering the cost of goods sold. EBIT and EBITDA margins remain negative, reflecting significant operating losses.

Balance Sheet

The company's balance sheet reveals a high debt-to-equity ratio of 1.54 in 2024, suggesting high leverage. The equity ratio decreased to 26.84%, indicating a decline in equity relative to total assets. Return on equity remains negative due to continued net losses, highlighting profitability challenges.

Cash Flow

Operating cash flow is negative and worsening, with a free cash flow of -22.79 million in 2024. The operating cash flow to net income ratio is 0.76, indicating cash flow issues in supporting net losses. The free cash flow to net income ratio is 0.79, suggesting limited free cash available relative to net losses.

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

MaaT Pharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:MAAT, the sentiment is Neutral. The current price of 4.68 is above the 20-day moving average (MA) of 4.67, below the 50-day MA of 4.94, and below the 200-day MA of 6.50, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 62.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:MAAT.

MaaT Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55 Neutral	€4.84B	16.40	-48.29%	2.19%	15.31%	-8.27%
ALCLS	52 Neutral	$189.25M	―	-58.55%	―	833.95%	38.17%
ALSEN	51 Neutral	€108.21M	―	-49.28%	―	―	55.02%
ABNX	47 Neutral	€53.70M	―	-57.56%	―	-1.92%	-9.26%
TNG	44 Neutral	€116.51M	―	-220.48%	―	-97.04%	-32.53%
MAAT	39 Underperform	€75.39M	―		―	44.34%	-27.37%